Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LYEL

LYEL - Lyell Immunopharma, Inc. Stock Price, Fair Value and News

$24.06-1.22 (-4.83%)
Market Closed

26/100

LYEL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

26/100

LYEL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$20.21

Target 3M

$23.62

Target 6M

$22.08

LYEL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LYEL Price Action

Last 7 days

-0.2%

Last 30 days

-33.3%

Last 90 days

45.6%

Trailing 12 Months

97.2%

LYEL RSI Chart

LYEL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LYEL Valuation

Market Cap

510.5M

Price/Earnings (Trailing)

-1.57

Price/Sales (Trailing)

12.5K

Price/Free Cashflow

-3.08

LYEL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$20.21

Target 3M

$23.62

Target 6M

$22.08

LYEL Fundamentals

LYEL Revenue

Revenue (TTM)

41.0K

Rev. Growth (Yr)

-55.88%

Rev. Growth (Qtr)

87.5%

LYEL Earnings

Earnings (TTM)

-325.7M

Earnings Growth (Yr)

12.87%

Earnings Growth (Qtr)

8.99%

LYEL Profitability

Return on Equity

-98.95%

Return on Assets

-79.83%

Free Cashflow Yield

-32.43%

LYEL Investor Care

Shares Dilution (1Y)

51.98%

Diluted EPS (TTM)

-22.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202565.0K60.0K41.0K0
2024112.8K95.5K78.3K61.0K
202363.5M42.4M21.3M130.0K
202229.2M47.7M66.2M84.7M
20218.9M8.5M10.0M10.7M
202003.0M5.4M7.8M
2019000657.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Lyell Immunopharma, Inc.

LYEL
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
 CEO
 WEBSITElyell.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES274

Lyell Immunopharma, Inc. Frequently Asked Questions

LYEL is the stock ticker symbol of Lyell Immunopharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Lyell Immunopharma, Inc. is 510.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check LYEL's fair value in chart for subscribers.

The fair value guage provides a quick view whether LYEL is over valued or under valued. Whether Lyell Immunopharma, Inc. is cheap or expensive depends on the assumptions which impact Lyell Immunopharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LYEL.

As of Wed Jan 28 2026, LYEL's PE ratio (Price to Earnings) is -1.57 and Price to Sales (PS) ratio is 12.45 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LYEL PE ratio will change depending on the future growth rate expectations of investors.